Source:http://linkedlifedata.com/resource/pubmed/id/11504082
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2001-8-15
|
pubmed:abstractText |
3-[123I]Iodo-alpha-methyl-L-tyrosine (IMT) is employed clinically as a tracer of amino acid transport in brain tumours using single-photon emission tomography (SPET). This study investigates the role of IMT SPET in the non-invasive histological grading and prognostic evaluation of cerebral gliomas. The files of patients investigated by IMT SPET in our clinic between 1988 and 1996 were evaluated retrospectively. Complete follow-up was available for 58 patients with cerebral gliomas investigated by IMT SPET shortly after tumour diagnosis. Seventeen patients had low-grade gliomas (WHO grade II), 14 had anaplastic gliomas (WHO grade III) and 27 had glioblastomas (WHO grade IV). Thirty-six cases were primary tumours and 22 cases, recurrences. Maximal and mean tumour-to-brain (T/B) ratios of IMT uptake at the first IMT SPET investigation were related to histological grading and survival time. Patients with low-grade gliomas showed significantly longer survival than patients with high-grade (grade III or IV) tumours. Gliomas without contrast enhancement on computed tomography or magnetic resonance imaging scans were associated with longer patient survival than tumours with contrast enhancement. The T/B ratios of IMT SPET showed no differences in relation to histological grading [WHO grade II: 1.73+/-0.59; WHO grade III: 1.74+/-0.38; WHO grade IV: 1.59+/-0.35, (mean+/-SD, T/B ratios of mean tumour uptake)]. The median survival time of patients with a high T/B ratio on IMT SPET was not significantly different from that of patients with a low T/B ratio (T/B ratio <1.6, 14.8 months; T/B ratio > or =1.6, 13.0 months). Thus, no evidence could be found for a relationship between IMT uptake in cerebral gliomas and either histological grading or survival time. Nevertheless, IMT SPET constitutes a useful method for the detection of primary and recurrent gliomas, determination of tumour extent and individual follow-up.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0340-6997
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
855-61
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:11504082-Adult,
pubmed-meshheading:11504082-Aged,
pubmed-meshheading:11504082-Brain Neoplasms,
pubmed-meshheading:11504082-Female,
pubmed-meshheading:11504082-Glioma,
pubmed-meshheading:11504082-Humans,
pubmed-meshheading:11504082-Iodine Radioisotopes,
pubmed-meshheading:11504082-Male,
pubmed-meshheading:11504082-Methyltyrosines,
pubmed-meshheading:11504082-Middle Aged,
pubmed-meshheading:11504082-Prognosis,
pubmed-meshheading:11504082-Radiopharmaceuticals,
pubmed-meshheading:11504082-Retrospective Studies,
pubmed-meshheading:11504082-Survival Rate,
pubmed-meshheading:11504082-Tomography, Emission-Computed, Single-Photon
|
pubmed:year |
2001
|
pubmed:articleTitle |
3-[123I]Iodo-alpha-methyl-L-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis.
|
pubmed:affiliation |
Clinic of Nuclear Medicine, Heinrich-Heine-University Düsseldorf, Germany.
|
pubmed:publicationType |
Journal Article
|